/images/ppid_59c68470-image-177003517289524746.webp)
What is the story about?
Multi-speciality hospital chain operator Jupiter Life Line Hospitals Ltd on Monday, February 2, reported a mixed set of numbers for the third quarter of FY26, with net profit declining even as revenue and operating performance showed steady growth year-on-year.
For the quarter, net profit fell 18.3% to ₹42.5 crore compared with ₹52 crore in the same period last year. Revenue grew 9.8% year-on-year to ₹365.3 crore from ₹332.8 crore, reflecting continued traction across its hospital operations.
At the operating level, EBITDA rose 9.7% to ₹83.9 crore against ₹76.5 crore a year ago. EBITDA margins, however, remained flat at 23% on a year-on-year basis, indicating stable cost management despite the pressure on the bottom line.
The performance underscores a divergence between operating growth and profitability, with higher revenues and EBITDA not translating into profit growth during the quarter. The company did not report any year-on-year expansion in margins, suggesting limited operating leverage in the period under review.
The Q3 outcome follows a strong top-line showing in the first quarter of FY26. In the April–June quarter ended June 30, 2025, Jupiter Life Line Hospitals reported a 1.4% year-on-year decline in net profit at ₹43.8 crore compared with ₹44.5 crore in the year-ago period.
Revenue from operations in the first quarter surged 20% to ₹348 crore from ₹289 crore a year earlier. EBITDA for the quarter increased 19.8% to ₹78.1 crore versus ₹65.2 crore, while EBITDA margins remained largely flat at 22.5% compared with 22.6% in the corresponding period last year.
The company had earlier highlighted that both revenue and EBITDA rose sharply in the April–June quarter, even as profit and margins stayed broadly unchanged on a year-on-year basis.
Also read: Jupiter Life Line Q1 Results | Revenue surges 20%; profit, margins flat
On the stock market, shares of Jupiter Life Line Hospitals Ltd closed lower on the NSE at ₹1,251.40, down ₹56.20 or 4.30%.
For the quarter, net profit fell 18.3% to ₹42.5 crore compared with ₹52 crore in the same period last year. Revenue grew 9.8% year-on-year to ₹365.3 crore from ₹332.8 crore, reflecting continued traction across its hospital operations.
At the operating level, EBITDA rose 9.7% to ₹83.9 crore against ₹76.5 crore a year ago. EBITDA margins, however, remained flat at 23% on a year-on-year basis, indicating stable cost management despite the pressure on the bottom line.
The performance underscores a divergence between operating growth and profitability, with higher revenues and EBITDA not translating into profit growth during the quarter. The company did not report any year-on-year expansion in margins, suggesting limited operating leverage in the period under review.
Q1FY26 performance snapshot
The Q3 outcome follows a strong top-line showing in the first quarter of FY26. In the April–June quarter ended June 30, 2025, Jupiter Life Line Hospitals reported a 1.4% year-on-year decline in net profit at ₹43.8 crore compared with ₹44.5 crore in the year-ago period.
Revenue from operations in the first quarter surged 20% to ₹348 crore from ₹289 crore a year earlier. EBITDA for the quarter increased 19.8% to ₹78.1 crore versus ₹65.2 crore, while EBITDA margins remained largely flat at 22.5% compared with 22.6% in the corresponding period last year.
The company had earlier highlighted that both revenue and EBITDA rose sharply in the April–June quarter, even as profit and margins stayed broadly unchanged on a year-on-year basis.
Also read: Jupiter Life Line Q1 Results | Revenue surges 20%; profit, margins flat
On the stock market, shares of Jupiter Life Line Hospitals Ltd closed lower on the NSE at ₹1,251.40, down ₹56.20 or 4.30%.
